200 Shares in Repligen Co. (NASDAQ:RGEN) Acquired by Sava Infond d.o.o.

Sava Infond d.o.o. bought a new stake in shares of Repligen Co. (NASDAQ:RGEN) in the fourth quarter, Holdings Channel reports. The fund bought 200 shares of the biotechnology company’s stock, valued at approximately $29,000.

Several other hedge funds also recently bought and sold shares of the company. Ballentine Partners LLC lifted its holdings in shares of Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 72 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in shares of Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 81 shares in the last quarter. MML Investors Services LLC raised its holdings in shares of Repligen by 2.7% during the 3rd quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 89 shares in the last quarter. GAMMA Investing LLC lifted its position in Repligen by 15.2% in the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after buying an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in shares of Repligen by 0.7% during the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after acquiring an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of RGEN opened at $133.41 on Friday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $184.98. The firm’s 50-day simple moving average is $154.21 and its two-hundred day simple moving average is $148.14. The stock has a market cap of $7.49 billion, a PE ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

RGEN has been the subject of several recent research reports. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price target for the company. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.